Pancreatic ductal adenocarcinoma (PDAC) is an aggressive human malignancy with a very poor 5-year survival rate of under 8%. Receptor tyrosine kinases (RTKs) are constitutively activated in PDACs. The atypical receptor-like tyrosine kinase RYK is overexpressed in several cancers and has been identified as a potential regulator of tumor signaling, but its role in PDAC remains little explored.